Profile data is unavailable for this security.
About the company
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
- Revenue in USD (TTM)158.86k
- Net income in USD-4.94m
- Incorporated2010
- Employees6.00
- LocationNexalin Technology Inc26072 MERIT CIRCLE, SUITE 106LAGUNA NIGUEL 92653United StatesUSA
- Phone+1 (949) 260-8090
- Websitehttps://nexalin.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hawkeye Systems Inc | 0.00 | -804.18k | 5.09m | 44.00 | -- | -- | -- | -- | -0.1186 | -0.1186 | 0.00 | -0.29 | 0.00 | -- | -- | -- | -66.07 | -330.11 | -- | -- | -- | -- | -- | -218.49 | -- | -2.78 | 10.45 | -- | -- | -- | 4.85 | -- | -- | -- |
| Vapotherm Inc | 70.07m | -54.94m | 5.22m | 182.00 | -- | -- | -- | 0.0745 | -8.62 | -8.62 | 11.00 | -11.02 | 0.8122 | 1.46 | 7.53 | 385,011.00 | -63.68 | -49.73 | -587.27 | -62.54 | 45.28 | 43.56 | -78.40 | -78.99 | 0.1259 | -1.27 | 2.59 | -- | 2.80 | 10.14 | 48.62 | -- | -10.38 | -- |
| Encision Inc | 6.87m | -448.00k | 5.88m | 31.00 | -- | 2.68 | -- | 0.857 | -0.0381 | -0.0381 | 0.5835 | 0.1863 | 1.64 | 1.96 | 7.84 | 221,520.00 | -10.69 | -1.07 | -14.05 | -1.46 | 50.54 | 52.27 | -6.52 | -0.613 | 1.08 | -6.22 | 0.1123 | -- | -4.17 | -3.44 | -393.90 | -- | 12.89 | -- |
| Fuse Medical Inc | 18.40m | 3.63m | 6.06m | 31.00 | 2.28 | -- | 1.64 | 0.3295 | 0.036 | 0.036 | 0.2307 | -0.0031 | 0.9593 | 0.7018 | 5.75 | 593,671.90 | 18.91 | 0.7504 | 48.45 | 1.35 | 64.95 | 54.98 | 19.72 | 0.6552 | 0.3143 | -1.13 | 1.12 | -- | -8.67 | -6.72 | 295.11 | 34.66 | -- | -- |
| Sonendo Inc | 40.19m | -57.74m | 6.36m | 216.00 | -- | 0.259 | -- | 0.1581 | -0.6125 | -0.5552 | 0.426 | 0.3482 | 0.4448 | 2.07 | 7.58 | 186,055.60 | -63.91 | -- | -78.82 | -- | 27.64 | -- | -143.67 | -- | 2.14 | -10.83 | 0.4695 | -- | 5.30 | -- | -6.78 | -- | -- | -- |
| BIOLASE Inc | 49.16m | -37.62m | 6.41m | 157.00 | -- | -- | -- | 0.1304 | -37.97 | -37.97 | 38.54 | 0.5726 | 1.34 | 2.38 | 8.68 | 313,146.50 | -56.30 | -49.28 | -115.21 | -85.80 | 34.02 | 35.27 | -41.97 | -50.72 | 0.683 | -6.61 | 0.8778 | -- | 1.45 | 1.27 | -30.39 | -- | 18.63 | -- |
| Sigyn Therapeutics Inc | 0.00 | -3.56m | 6.43m | 5.00 | -- | -- | -- | -- | -3.04 | -3.04 | 0.00 | -3.28 | 0.00 | -- | -- | 0.00 | -724.37 | -493.15 | -- | -- | -- | -- | -- | -10,223.96 | 0.0199 | -1.92 | -- | -- | -- | -- | -41.51 | -- | -- | -- |
| Arch Therapeutics Inc | 130.55k | -8.43m | 6.58m | 8.00 | -- | -- | -- | 50.38 | -3.68 | -3.68 | 0.0425 | -2.45 | 0.0833 | 0.0637 | -- | 16,318.75 | -538.25 | -188.28 | -- | -804.63 | 33.37 | -- | -6,458.14 | -26,945.92 | 0.0164 | -1.27 | -- | -- | 383.83 | -- | -32.35 | -- | -21.76 | -- |
| Predictive Oncology Inc | 1.96m | -14.78m | 6.69m | 34.00 | -- | 1.63 | -- | 3.41 | -3.66 | -3.66 | 0.4853 | 0.9977 | 0.1099 | 1.71 | 4.95 | 57,642.65 | -82.89 | -91.80 | -108.54 | -126.29 | 64.18 | 64.64 | -754.19 | -1,419.99 | 1.35 | -- | 0.0093 | -- | 18.24 | 4.75 | 45.67 | -- | 5.44 | -- |
| Vivos Therapeutics Inc | 13.36m | -15.64m | 6.87m | 114.00 | -- | 10.00 | -- | 0.5144 | -11.00 | -11.00 | 8.73 | 0.2131 | 0.9247 | -- | 31.59 | 117,219.30 | -108.24 | -89.72 | -243.30 | -149.70 | 58.90 | 70.20 | -117.06 | -113.15 | -- | -- | 0.00 | -- | -13.87 | 29.48 | 43.04 | -- | -8.48 | -- |
| Neurometrix Inc | 5.27m | -7.98m | 7.72m | 26.00 | -- | 0.4068 | -- | 1.47 | -6.32 | -6.32 | 4.20 | 9.44 | 0.2381 | 1.25 | 10.08 | 202,700.40 | -36.07 | -23.24 | -38.94 | -27.26 | 61.97 | 59.17 | -151.51 | -48.88 | 10.11 | -- | 0.00 | -- | -28.52 | -18.18 | -47.84 | -- | 5.03 | -- |
| Nexalin Technology Inc | 158.86k | -4.94m | 8.55m | 6.00 | -- | 3.68 | -- | 53.83 | -0.6676 | -0.6676 | 0.0215 | 0.3129 | 0.0363 | 0.1778 | 44.01 | 26,476.67 | -112.76 | -- | -139.94 | -- | 82.54 | -- | -3,110.58 | -- | 4.75 | -- | 0.00 | -- | -91.62 | -- | -173.80 | -- | -- | -- |
| Citrine Global Corp | 0.00 | -2.38m | 9.66m | 18.00 | -- | -- | -- | -- | -0.0025 | -0.0025 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -173.12 | -298.98 | -- | -964.26 | -- | -- | -- | -4,814.84 | -- | -5.41 | -- | -- | -- | -- | 41.43 | -- | -5.44 | -- |
| Biomerica Inc | 5.41m | -6.35m | 10.65m | 62.00 | -- | 1.36 | -- | 1.97 | -0.3789 | -0.3789 | 0.3224 | 0.4642 | 0.5827 | 2.28 | 5.74 | 87,180.80 | -68.45 | -43.55 | -83.73 | -50.32 | 11.41 | 15.75 | -117.46 | -55.86 | 3.37 | -- | 0.00 | -- | -71.71 | -0.8229 | -57.58 | -- | -9.76 | -- |
| PetVivo Holdings Inc | 1.05m | -10.63m | 11.10m | 25.00 | -- | 10.85 | -- | 10.61 | -0.8694 | -0.8694 | 0.0842 | 0.06 | 0.3375 | 1.21 | 2.04 | 41,841.60 | -343.12 | -209.90 | -715.73 | -504.64 | 51.41 | 20.27 | -1,016.55 | -2,297.21 | 0.6169 | -2,268.84 | 0.1392 | -- | 693.46 | 260.32 | -73.83 | -- | 51.73 | -- |
| SINTX Technologies Inc | 2.78m | -8.88m | 11.36m | 43.00 | -- | 0.4765 | -- | 4.09 | -1.95 | -1.95 | 0.3711 | 0.1943 | 0.138 | 1.62 | 5.84 | 64,534.88 | -44.03 | -45.71 | -57.11 | -57.36 | 67.96 | 58.47 | -318.99 | -681.80 | 1.67 | -- | 0.0229 | -- | 68.29 | 94.24 | 49.75 | -- | 54.10 | -- |
Data as of May 23 2024. Currency figures normalised to Nexalin Technology Inc's reporting currency: US Dollar USD
0.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Mar 2024 | 38.87k | 0.52% |
| Jane Street Capital LLCas of 31 Mar 2024 | 11.31k | 0.15% |
| Tower Research Capital LLCas of 31 Mar 2024 | 9.08k | 0.12% |
| UBS Securities LLCas of 31 Mar 2024 | 4.17k | 0.06% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 44.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
